Intensity Therapeutics (INTS)
Develops INT230-6, a tumor-injection treatment candidate for solid cancers.
Something off on this page? Send us feedback.
Develops INT230-6, an investigational tumor-injection formulation intended to destroy solid tumors locally and encourage immune recognition. Future revenue would come from approved product sales or licensing; none is approved, and clinical work and manufacturing are outsourced.
Develops INT230-6, an investigational tumor-injection formulation combining established cytotoxic drugs with the DfuseRx platform's SHAO dispersion enhancer. Intended to destroy an injected solid tumor locally, it is designed to expose tumor-specific antigens and encourage systemic immune recognition. No approved or commercial product is disclosed.
Advances that candidate in randomized studies for soft-tissue sarcoma and presurgical triple-negative breast cancer, after earlier research in refractory and metastatic solid tumors. Clinical development spans the United States, Canada, Europe, Australia, Switzerland, and France.
Operates through a small virtualized organization that outsources clinical work and all manufacturing. The pipeline depends on INT230-6, regulatory approvals, trial funding and execution, and qualified sole suppliers for components and finished product.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 19, 2026 | H.C. Wainwright | Target | Target: $5 | Target: $7 |
| Aug 11, 2026 | Industrial Alliance Securities | Target | Target: — | Target: $15 |
| Aug 12, 2025 | Brookline Capital | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.5M · Total debt $95.0K · Total assets $11.5M · Shareholders' equity $9.2M
- Revenue
- $0
- Operating income
- −$3.1M
- Net income
- −$3.0M
No dividends on record.
| Institutions | 35.80% | 1.17M shares | |
|---|---|---|---|
| 18 holders · as of Jun 30, 2026 | |||
| Insiders | 3.92% | 127.9K shares | |
| 3 holders · as of Jul 1, 2026 | |||
| Other | 60.28% | 1.97M shares | |
| remainder | |||
3.26M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (3.26M in the company's Sep 23, 2026 report, 2.70M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Kingsbury Capital Investment Advisors LLCInstitution | 15.21% | 496,493 | as of Jun 30, 2026 |
KMT Wealth Management, LLCInstitution | 15.21% | 496,493 | as of Jun 30, 2026 |
Lewis H. BenderInsiderdirector, officer: President and CEO | 3.63% | 118,549 | filed Mar 30, 2026 |
Sentinus, LLCInstitution | 0.82% | 26,723 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.81% | 26,569 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Replimune Group
Closest tumor-injection immunotherapy platform rival.
- Amgen
Approved intralesional oncolytic therapy sets a high bar.
- Novartis (ADR)
Pazopanib is a direct investigator-choice comparator in sarcoma.
- Johnson & Johnson
Trabectedin contests late-line liposarcoma and leiomyosarcoma.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Intensity Therapeutics | $4.09 | +1.87% | $10.8M | — | — | — | — |
| Replimune Group | $12.91 | −4.16% | $1.13B | — | — | — | — |
| Amgen | $407.12 | −0.76% | $221.41B | 25.5 | 17.4 | 5.8 | +9.7% |
| Novartis (ADR) | $142.63 | +0.95% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Johnson & Johnson | $268.34 | −0.32% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Median | 25.5 | 17.4 | 5.8 | +6.6% |